An observational study in Fabry Disease, sponsored by Chiesi Italia. Recruiting at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Chiesi Italia (part of Chiesi Farmaceutici S.p.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2026, is one of 5 observational ones, and was the 10th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United States, Austria, France and 3 more countries
Ages 2–17
Chiesi Farmaceutici S.p.A. · Sites in United States, Germany, Italy and 2 more countries
Women only
Chiesi Farmaceutici S.p.A. · Sites in United States, Slovenia, United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in Japan
Ages 13–70
By country, each count listing its studies:
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4
First in 2018; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 75 is below the median of 100 across 122 observational studies indexed under Fabry Disease.
Median enrollment 26 across the 4 interventional studies, 75 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chiesi Italia, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Chiesi Italia is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
1 of the studies in Fabry Disease by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05710692Phase 3Chiesi Farmaceutici S.p.A.Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
Adults patients who have a genetically confirmed diagnosis of Fabry disease and are being treated or plan to initiate treatment with pegunigalsidase alfa as per clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients whit genetically confirmed diagnosis of Fabry disease being treated or planning to start treatment with Pegunigalsidase alfa according to clinical practice. Participants will be required to meet the inclusion and exclusion criteria and sign informed consent to be enrolled in the study.
Drug: pegunigalsidase alfa
Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
Also known as: Elfabrio
Assessment of structural abnormalities of the left ventricle
Changes from baseline in structural abnormalities of the left ventricle assessed by echocardiography and defined by the presence of Left Ventricular Hypertrophy.
Time frame: 24 months
Assessment of left ventricular diastolic function
Changes from baseline in left ventricular diastolic function by echocardiography. Diastolic dysfunction will be assessed using early to late diastolic trans-mitral flow velocity.
Time frame: 12 and 24 months
Assessment of renal function
Changes from baseline in renal function by estimated Glomerular Filtration Rate.
Time frame: 6, 12, 18 and 24 months
Assessment of peak oxygen uptake (pVO2)
Changes from baseline in peak oxygen uptake (pVO2) using cardiopulmonary exercise testing (CPET).
Time frame: 24 months
Assessment of carbon dioxide production (VCO2)
Changes from baseline in carbon dioxide production (VCO2) using cardiopulmonary exercise testing (CPET).
Time frame: 24 months
Assessment of NT-pro-BNP and high sensitivity cardiac troponin levels
Changes from baseline in NT-pro-BNP and high sensitivity cardiac troponin levels.
Time frame: 6, 12,18 and 24 months
Assessment of Cardiovascular Magnetic Resonance (CMR)
Changes from baseline in CMR assessed using T1 mapping to achieve myocardial tissue characterization.
Time frame: 12 and 24 months
Assessment of proteinuria and microalbuminuria
Changes from baseline in proteinuria and microalbuminuria assessed on 24-hour urine sample.
Time frame: 6, 12, 18 and 24 months
Assessment of Globotriaosylsphingosine (lyso-Gb3)
Changes from baseline in blood concentration of lyso-Gb3
Time frame: 3, 6, 12 and 24 months
Assessment of QoL outcomes using the Short Form Health Survey 36 (SF-36)
Changes from baseline in SF-36 score. It is a disease-specific questionnaire consisting of eight domains, each represented by a scale calculated as the weighted sum of responses in the respective sections. Each domain score ranges from 0 to 100, with all questions given equal weight. A score of 0 indicates the worst possible health status, while a score of 100 represents the best possible health status.
Time frame: 12 and 24 months
Assessment of QoL outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Changes from baseline in KCCQ scores. It measures patient's perception of their health status, focusing on heart failure symptoms, the impact on physical and social functioning, and the overall effect of heart failure on their QoL within a 2-week recall period. It evaluates seven domains, with scores ranging from 0 to 100, where lower scores indicate more severe symptoms or limitations, while a score of 100 represents no symptoms, no limitations, and excellent quality of life.
Time frame: 12 and 24 months
Assessment of severity of neuropathic pain using Chronic Pain Grade (CPG)
Changes from baseline in CPG score. It is a 7-item questionnaire that evaluates chronic pain severity experienced over the past six months. Pain intensity is rated from 0 (no pain) to 10 ("pain as bad as it can be"). Scores for pain intensity and disability are combined to classify the overall severity of chronic pain into four grades, ranging from Grade 0 (no pain) to Grade IV (high disability, severely limiting).
Time frame: 12 and 24 months
Assessment of severity of neuropathic pain using Short Form of the Brief Pain Inventory (BPI-SF)
Changes from baseline in BPI-SF score. It is a 9-item questionnaire assessing Pain Intensity and Pain Interference, as its impact on daily functions, over the past 24 hours. Pain intensity is rated on a 0 (no pain) to 10 (pain as bad as you can imagine) scale, across four measures: worst, least, average, and current pain. Pain interference with daily activities is also scored from 0 (no interference) to 10 (completely interferes).
Time frame: 12 and 24 months
Assessment of gastrointestinal symptoms using the Gastrointestinal Symptoms Rating Scale (GSRS)
Changes from baseline in GSRS score. It is a 15-item questionnaire designed to assess changes in gastrointestinal symptoms across five clusters: reflux, abdominal pain, indigestion, diarrhea, and constipation. The GSRS uses a seven-point Likert-type scale, with scores ranging from 1 (no troublesome symptoms) to 7 (very troublesome symptoms).
Time frame: 12 and 24 months
Assessment of specific Fabry disease ocular findings
Number of patients with presence of specific Fabry disease ocular findings (i.e. cornea verticillate) by slit lamp
Time frame: Baseline, 12 and 24 months
Adverse events
Number of AEs
Time frame: 24 months
Adverse drug reactions to pegunigalsidase alfa
Number of ADRs
Time frame: 24 months
Anti-drug antibodies (ADAs) testing
Number of patients with ADAs
Time frame: 24 months
Infusion-Related Reactions (IRRs)
Number of patients and occurrence of IRRs
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Feb 2029, 32 months after the start.
Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 32 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.